- Home
- KR vs RVMD Comparison
KR vs RVMD Comparison
Compare KR & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KR | RVMD |
|---|---|---|
| Founded | 1883 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Food Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.1B | 30.1B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | KR | RVMD |
|---|---|---|
| Price | $57.34 | $198.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | $74.25 | ★ $140.84 |
| AVG Volume (30 Days) | ★ 6.8M | 1.7M |
| Earning Date | 03-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $147,642,000,000.00 | N/A |
| Revenue This Year | $4.39 | N/A |
| Revenue Next Year | $2.30 | $533.02 |
| P/E Ratio | $38.82 | ★ N/A |
| Revenue Growth | ★ 0.35 | N/A |
| 52 Week Low | $54.15 | $34.15 |
| 52 Week High | $76.58 | $198.30 |
Technical Indicators
Market Signals| Indicator | KR | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 61.86 |
| Support Level | $55.20 | $177.04 |
| Resistance Level | $64.44 | N/A |
| Average True Range (ATR) | 1.35 | 7.37 |
| MACD | 0.06 | 0.23 |
| Stochastic Oscillator | 43.72 | 90.72 |
Price Performance
Historical ComparisonAbout KR Kroger Company (The)
Founded in 1883, Kroger is the largest pure-play supermarket operator in the United States, operating roughly 2,700 stores across more than 30 banners. Kroger's business is primarily grocery-led (roughly 78% of sales), spanning fresh food and private-label offerings, complemented by fuel centers (9%) and pharmacies (12%). The firm also generates income from advertising, data analytics, and manufacturing.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.